Initial testing of Aplidin by the pediatric pre-clinical testing program

Christopher L. Morton; Peter J. Houghton; Richard Gorlick; E. Anders Kolb; Richard Lock; Hernan Carol; Stephen T. Keir; C. Patrick Reynolds; Min H. Kang; John M. Maris; Catherine Billups; Malcolm A. Smith

doi:10.1002/pbc.21976

Initial testing of Aplidin by the pediatric pre-clinical testing program

Christopher L. Morton, Peter J. Houghton, Richard Gorlick, E. Anders Kolb, Richard Lock, Hernan Carol, Stephen T. Keir, C. Patrick Reynolds, Min H. Kang, John M. Maris, Catherine Billups, Malcolm A. Smith

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Aplidin was tested in vitro at concentrations ranging from from 0.1 nM to 1.0 μM and in vivo at a dose of 0.6 mg/kg administered intraperitoneally on an every 4 days x 3-schedule that was repeated at day 21. In vitro, Aplidin was most active against acute lymphoblastic leukemia (ALL) cell lines. In vivo, Aplidin induced significant differences in EFS distribution in 12 of 28 (43%) solid tumor models and 2 of 6 evaluable ALL models. Aplidin showed potent in vitro activity and induced significant in vivo tumor growth inhibition in some xenografts, but did not induce tumor regressions.

Original language	English (US)
Pages (from-to)	509-512
Number of pages	4
Journal	Pediatric Blood and Cancer
Volume	53
Issue number	3
DOIs	https://doi.org/10.1002/pbc.21976
State	Published - Sep 2009
Externally published	Yes

Keywords

Aplidin
Developmental therapeutics
Pre-clinical testing

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.1002/pbc.21976

Cite this

@article{46be7b1da96146d085d8ffb9550a3afb,

title = "Initial testing of Aplidin by the pediatric pre-clinical testing program",

abstract = "Aplidin was tested in vitro at concentrations ranging from from 0.1 nM to 1.0 μM and in vivo at a dose of 0.6 mg/kg administered intraperitoneally on an every 4 days x 3-schedule that was repeated at day 21. In vitro, Aplidin was most active against acute lymphoblastic leukemia (ALL) cell lines. In vivo, Aplidin induced significant differences in EFS distribution in 12 of 28 (43%) solid tumor models and 2 of 6 evaluable ALL models. Aplidin showed potent in vitro activity and induced significant in vivo tumor growth inhibition in some xenografts, but did not induce tumor regressions.",

keywords = "Aplidin, Developmental therapeutics, Pre-clinical testing",

author = "Morton, {Christopher L.} and Houghton, {Peter J.} and Richard Gorlick and Kolb, {E. Anders} and Richard Lock and Hernan Carol and Keir, {Stephen T.} and Reynolds, {C. Patrick} and Kang, {Min H.} and Maris, {John M.} and Catherine Billups and Smith, {Malcolm A.}",

year = "2009",

month = sep,

doi = "10.1002/pbc.21976",

language = "English (US)",

volume = "53",

pages = "509--512",

journal = "Medical and Pediatric Oncology",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "3",

}

TY - JOUR

T1 - Initial testing of Aplidin by the pediatric pre-clinical testing program

AU - Morton, Christopher L.

AU - Houghton, Peter J.

AU - Gorlick, Richard

AU - Kolb, E. Anders

AU - Lock, Richard

AU - Carol, Hernan

AU - Keir, Stephen T.

AU - Reynolds, C. Patrick

AU - Kang, Min H.

AU - Maris, John M.

AU - Billups, Catherine

AU - Smith, Malcolm A.

PY - 2009/9

Y1 - 2009/9

N2 - Aplidin was tested in vitro at concentrations ranging from from 0.1 nM to 1.0 μM and in vivo at a dose of 0.6 mg/kg administered intraperitoneally on an every 4 days x 3-schedule that was repeated at day 21. In vitro, Aplidin was most active against acute lymphoblastic leukemia (ALL) cell lines. In vivo, Aplidin induced significant differences in EFS distribution in 12 of 28 (43%) solid tumor models and 2 of 6 evaluable ALL models. Aplidin showed potent in vitro activity and induced significant in vivo tumor growth inhibition in some xenografts, but did not induce tumor regressions.

AB - Aplidin was tested in vitro at concentrations ranging from from 0.1 nM to 1.0 μM and in vivo at a dose of 0.6 mg/kg administered intraperitoneally on an every 4 days x 3-schedule that was repeated at day 21. In vitro, Aplidin was most active against acute lymphoblastic leukemia (ALL) cell lines. In vivo, Aplidin induced significant differences in EFS distribution in 12 of 28 (43%) solid tumor models and 2 of 6 evaluable ALL models. Aplidin showed potent in vitro activity and induced significant in vivo tumor growth inhibition in some xenografts, but did not induce tumor regressions.

KW - Aplidin

KW - Developmental therapeutics

KW - Pre-clinical testing

UR - http://www.scopus.com/inward/record.url?scp=67651204923&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67651204923&partnerID=8YFLogxK

U2 - 10.1002/pbc.21976

DO - 10.1002/pbc.21976

M3 - Article

C2 - 19418543

AN - SCOPUS:67651204923

VL - 53

SP - 509

EP - 512

JO - Medical and Pediatric Oncology

JF - Medical and Pediatric Oncology

SN - 1545-5009

IS - 3

ER -

Initial testing of Aplidin by the pediatric pre-clinical testing program

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this